Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Bioventus Raises 2024 Guidance: Now Expects Net Sales Of $535M-$550M (Prior $520M-$535M) Vs. $528.033M Est., And Adj. EPS Of $0.25 To $0.33 (Prior $0.12-$0.20) Vs. $0.16 Est.

Author: Benzinga Newsdesk | May 07, 2024 07:17am

2024 Financial Guidance:

Based on strong execution and significant momentum across the business, Bioventus is raising financial guidance for full-year 2024. The Company now expects:

  • Net sales of $535 million to $550 million—An increase of $15 million from previous guidance
  • Adjusted EBITDA* of $94 million to $99 million—An increase of $5 million from previous guidance
  • Non-GAAP EPS* of $0.25 to $0.33—An increase of $0.13 from previous guidance

Posted In: BVS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist